Tuesday, May 20, 2008

Liposome and polymer technologies target delivery of anti-cancer agents

Like leaving simple but extremely attractive food out for mice to eat and lacing it with disguised poison, the NeoPharm company's NeoLipid® technology entices tumor cells to consume lots of fats (lipids) that are secretly loaded with drugs. The liposomal product--a microscopic spherical particle with an outside fat layer that encloses a compartment you can put liquids in--feeds the hungry tumor cell both the fats it craves and the anti-cancer drugs that will lead to its death.

Other researchers are studying carriers like polymer drug conjugates (pairs or other combinations) which can also be programmed to say when and where they will release their drug load. One problem is some of these polymers can't carry as much of the desired anti-cancer agents as the liposomes. Another possibility being studied is dendrimers, which are working well in mice--without poisoning them--but these haven't been used with humans yet. And although that story doesn't say so, according to this site dendrimers fall into the nanotechnology category and may carry their own risks.

Always glad to read about research into methods that try to spare the rest of the patient while trying to get to the bad cells.

Labels: , , , , , ,

Monday, March 17, 2008

More on non-invasive cancer treatments

Scientists are getting more creative in finding ways to treat cancer cells without destroying surrounding tissue. A Chicago-based company NEOPHARM is working on a protein with one part that targets tumors (IL13) and the other that kills the cancer cell (PE38). Here's how it works:
The two-part recombinant protein is CINTREDEKIN BESUDOTOX (IL13-PE38QQR). Malignant glioma cells carry IL13 receptors , but healthy brain cells almost never do. The protein is designed to bind to IL13 receptors on the tumor like a key fits in a lock. The cancer cell latches onto and absorbs the IL13 and the attached PE38. As a result, the cancer cell dies. Healthy brain cells are expected to be unharmed because they do not have the IL13 receptors, and thus do not ingest the PE38.
This drug has already been in a Phase 3 clinical trial. And the best part is the FDA is so excited about this work that it has designated it an Orphan Drug (meaning it won't require prescription drug user fees) both in Europe and the US. They've also included it in their new Continuous Marketing Application pilot program--and THAT means the FDA is all over helping develop the drug. Congratulations to NEOPHARM investigators.

I've heard some horror stories about how the FDA has been known to stand in the way of certain developments. So it's nice to see them out there finding ways to get good stuff released.

Labels: , , , , , ,